摘要
目的探究替格瑞洛片治疗复杂冠状动脉粥样硬化性心脏病(冠心病)的临床疗效和安全性。方法190例复杂冠心病患者,通过电脑随机分组的方式分为研究组和参照组,每组95例。参照组患者采用硫酸氢氯吡格雷治疗,研究组患者采用替格瑞洛片治疗。比较两组患者治疗效果,治疗前后心功能指标、血清N末端B型钠尿肽前体(NT-proBNP)水平、健康调查简表(SF-36)评分,治疗后不良反应发生情况。结果研究组患者治疗总有效率96.84%高于参照组的86.32%,差异具有统计学意义(P<0.05)。治疗前,两组患者的左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、6 min步行距离比较差异无统计学意义(P>0.05);治疗后,研究组患者的LVEF(48.10±2.20)%高于参照组的(43.34±2.20)%,LVEDD(52.60±2.20)mm低于参照组的(57.24±2.20)mm,6 min步行距离(420.20±3.20)m长于参照组的(310.50±3.22)m,差异具有统计学意义(P<0.05)。治疗前,两组患者的血清NT-proBNP水平比较差异无统计学意义(P>0.05);治疗后,研究组患者的血清NT-proBNP(668.60±18.40)pg/ml低于参照组的(775.84±23.50)pg/ml,差异具有统计学意义(P<0.05)。研究组患者治疗后不良反应发生率4.21%显著低于参照组的12.63%,差异具有统计学意义(P<0.05)。治疗前,两组患者躯体功能、生理职能、总体健康评分比较差异无统计学意义(P>0.05);治疗后,研究组患者躯体功能、生理职能、总体健康评分显著高于参照组,差异具有统计学意义(P<0.05)。结论替格瑞洛片对复杂冠心病患者的治疗效果更好,具有较高的临床治疗价值。
Objective To investigate the clinical efficacy and safety of ticagrelor tablets in the treatment of complex coronary heart disease.Methods A total of 190 patients with complex coronary heart disease were randomly divided into a study group and a reference group,with 95 cases in each group.The reference group was treated with clopidogrel bisulfate,and the study group was treated with ticagrelor tablets.Both groups were compared in terms of therapeutic effect,cardiac function index and serum N-terminal B-type natriuretic peptide(NT-proBNP)level,36-item short-form health survey(SF-36)score before and after treatment,occurrence of adverse reactions after treatment.Results The total effective rate of 96.84%in the study group was higher than that of 86.32%in the reference group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in left ventricular ejection fraction(LVEF)and left ventricular end diastolic diameter(LVEDD)and 6-min walking distance between the two groups(P>0.05).After treatment,LVEF of(48.10±2.20)%in the study group was higher than that of(43.34±2.20)%in the reference group;LVEDD of(52.60±2.20)mm in the study group was lower than that of(57.24±2.20)mm in the reference group;the 6-min walking distance of(420.20±3.20)m in the study group was longer than that of(310.50±3.22)m in the reference group;the differences were statistically significant(P<0.05).Before treatment,there was no statistically significant difference in serum NT-proBNP level between the two groups(P>0.05).After treatment,the serum NT-proBNP of(668.60±18.40)pg/ml in the study group was lower than that of(775.84±23.50)pg/ml in the reference group,and the difference was statistically significant(P<0.05).After treatment,the incidence of adverse reactions in the study group was 4.21%,which was significantly lower than that of 12.63%in the reference group,and the difference was statistically significant(P<0.05).Before treatment,there were no statistically significant
作者
张贵峰
康志钦
ZHANG Gui-feng;KANG Zhi-qin(Department of Cardiovascular Medicine,Hui'an County Hospital,Quanzhou 362100,China)
出处
《中国现代药物应用》
2023年第23期6-9,共4页
Chinese Journal of Modern Drug Application
